Therapeutics, Limited (“Tenpoint”) and Visus Therapeutics, Inc., (“Visus”) announce today
the completion of their merger to create an entirely new chapter in ophthalmic therapeutic
medicines aimed at rejuvenating the aging eye. The merger brings together a late-stage,
potentially best-in-class, presbyopia-correcting eye drop, BRIMOCHOL™ PF, on track for
NDA filing in 1H, 2025, with a promising pipeline of innovative therapeutics.
The merger unites a strong syndicate of institutional investors who are committed to
advancing BRIMOCHOL™ PF through marketing approval to patients worldwide while
further advancing Tenpoint’s pipeline into clinical development.
Tenpoint’s pipeline is comprised of three innovative programs aimed at rejuvenating the
aging eye:

• BRIMOCHOL™ PF, a once-a-day, all day, presbyopia-correcting eye drop with a
  differentiated profile. =BRIMOCHOL™ PF is a unique and patent-protected
  combination of carbachol, a potent miotic, and brimonidine, an alpha2-agonist.
  This combination enhances peak efficacy and extends duration; and through the
  vasoconstrictive properties of brimonidine, helps reduce ocular redness offering a
  potentially superior treatment for presbyopia.

• TPT-161, a novel small molecule designed to reverse cataract formation in aging
  adults.

• TPT-005, a cell therapy targeting RPE cell replacement for geographic atrophy.

To support the continued development of these programs, Tenpoint will shortly embark
on a Crossover financing round with insider participation to further fund the completion of
clinical studies for BRIMOCHOLTM PF, and the commercialization preparations for a 1H,
2026 launch of BRIMOCHOLTM PF into the US market.
As part of the leadership transition, Mr. Henric Bjarke has been appointed Chief Executive
Officer of the newly merged company.

“As we relaunch Tenpoint as a combined entity with Visus, we are excited to lead with a
robust Ophthalmology pipeline, starting with BRIMOCHOL™ PF, a near-term therapeutic
medicine for presbyopia alongside other innovative therapies to treat Cataract and
Geographic Atrophy,” said Henric Bjarke, CEO. “With our combined teams, we have the
right expertise to develop and successfully launch innovative products with the potential
to be first and best in class in ophthalmic medicines.”

Mr. Bjarke brings extensive commercial and operational leadership experience in the
biopharmaceutical industry, with a focus on ophthalmology, hematology, and orphan
diseases. He has held senior roles at several successful companies including, Inozyme
Pharma, Ophthotech, Alexion Pharmaceuticals, (OSI) Eyetech, and Pharmacia.

“The merger of Tenpoint and Visus is a pivotal moment in the evolution of both companies.
As Board Chair, I am excited about the opportunity to collaborate with the new leadership
team to commercialize BRIMOCHOL™ PF and advance innovative products into clinical
development to meet unmet needs in ocular diseases,” said David Guyer, MD, Chairman
of the Board.

About Tenpoint Therapeutics
Tenpoint Therapeutics Limited is a global, clinical-stage biotech company developing
groundbreaking treatments to rejuvenate vision in the aging eye. Its pipeline includes
paradigm-shifting treatments for ophthalmic indications with the greatest need and global
market potential, including presbyopia, cataracts and geographic atrophy. Its lead asset,
BRIMOCHOLTM PF, is a novel, pupil-modulating therapeutic designed to correct the loss
of near vision associated with presbyopia, a condition that afflicts approximately 2 billion
people globally. BRIMOCHOLTM PF has completed its first Phase 3 pivotal trial (BRIO-I)
and will complete the second pivotal study, BRIO-II, in 2025. This topical ophthalmic is
poised for launch in 2026. Tenpoint’s leadership team includes ophthalmic industry
luminaries with track records of successful approvals and commercialization of
blockbuster drugs. A privately held company, Tenpoint Therapeutics is backed by AdBio
Partners, British Patient Capital, Eight Roads, EQT Life Sciences, F-Prime Capital,
Hillhouse Capital Management, Qiming Venture Partners USA, Sofinnova Partners, and
UCL Technology Fund. To learn more visit tenpointtherapeutics.com and connect on
LinkedIn.

• Share